Pt No Age Sex Diagnosis Source Cytogenetics FLT3/ITD mutation Induction chemo Response Υ=CR Ν=No CR ROSlow % of total CD34+ ROS Relative MFI 1 60 F sAML PB del(5q) negative 7+3 regimen Ν 2.08 0.604 2 82 F sAML PB N/D N/D No treatment N/A 0.24 8.853 3 65 F de novo AML BM normal negative 7+3 regimen Υ 0.58 2.259 4 56 M sAML BM complex negative 7+3 regimen Ν 0.69 3.777 5 68 M sAML PB trisomy 8 N/D 5-azacitidine Ν 2.18 2.639 6 69 M sAML PB normal N/D 5-azacitidine Ν 3.11 1.283 7 50 M de novo AML PB inv(16)(p13.1q22) negative 7+3 regimen Υ 0.34 3.741 8 74 M de novo AML BM N/D N/D No treatment Ν 0.3 3.051 9 66 F de novo AML PB del(20q) N/D 7+3 regimen N 2.34 11.095 10 74 F de novo AML PB N/A positive 7+3 regimen Ν 0.31 6.001 11 77 M de novo AML PB N/D positive LD-AraC Ν 0.6 1.520 12 72 M de novo AML PB normal positive 7+3 regimen Υ 0.4 3.839 13 73 M sAML PB trisomy 8 negative 7+3 regimen Υ 1.41 1.270 14 78 M de novo AML PB N/D positive 7+3 regimen Ν 1.92 1.294 15 39 M de novo AML PB normal N/D 7+3 regimen Υ 0.29 2.460 16 76 F de novo AML PB N/A N/A N/A N/A 1.27 3.102 17 51 F de novo AML PB monosomy 7 negative 7+3 regimen Ν 0.84 2.360 18 35 M de novo AML BM normal N/D 7+3 regimen Υ 2.69 8.991 19 25 F de novo AML PB inv(16)(p13.1q22) negative 7+3 regimen Υ 0.41 3.236 20 77 M de novo AML BM N/A negative N/A N/A 2.17 3.819 21 66 M de novo AML PB normal negative 7+3 regimen Ν 0.61 8.093 22 76 F de novo AML PB N/A positive No treatment N/A 0.35 2.698 23 75 F sAML BM N/D N/D No treatment N/A 4.99 5.720 24 81 F de novo AML PB N/A positive LD-AraC Ν 0.2 1.722 25 56 M de novo AML PB N/A N/D 7+3 regimen Ν 0.4 11.529 26 77 M de novo AML PB N/A N/A No treatment N/A 0.34 3.340 27 75 M sAML PB N/A N/A No treatment N/A 1.2 6.484 28 49 M sAML PB monosomy 7 N/D 7+3 regimen Ν 0.52 3.965 29 83 M sAML PB normal N/D LD-AraC Ν 0.79 6.090 30 60 M de novo AML BM N/D N/D No treatment N/A 0.52 7.919 31 76 F de novo AML PB N/D N/D No treatment N/A 0.8 1.389 32 68 M de novo AML PB complex N/D No treatment N/A 0.5 1.811 33 63 M de novo AML BM normal negative 7+3 regimen Ν 0.2 3.969 34 78 M sAML PB N/A N/A No treatment N/A 1.22 6.427 35 72 F de novo AML BM normal N/A No treatment N/A 1.4 2.366 36 68 M sAML PB del(12)(p11.2) N/D 5-azacitidine N 1.5 2.899 37 74 M sAML BM normal N/D 5-azacitidine N 0.43 0.789 38 67 M de novo AML BM normal N/A 7+3 regimen N 0.7 3.415 39 66 M de novo AML PB Monosomy 7q, trisomy 1q N/A 7+3 regimen N 1 6.335 40 69 M sAML PB normal N/D 5-azacitidine N 0.5 5.292 41 51 F de novo AML PB inv(16)(p13.1q22) negative 7+3 regimen Y 0.78 4.43 42 72 M sAML PB N/A N/D 5-azacitidine N 0.81 6.28 43 60 M de novo AML BM normal negative 7+3 regimen N 0.2 4.62 44 48 M de novo AML BM normal negative 7+3 regimen N 0.4 5.02

Table 1:Parameters of patients included in study. AML, acute myeloid leukemia; CG, cytogenetics; F, female; M, male; MDS, myelodysplastic syndrome; sAML, AML evolving from antecedent MDS; N, normal; N/A, not available; N/D, not done